1. Home
  2. Healthcare
  3. Asthma Drug Market Size, Share, Outlook 2032

Asthma Drug Market Size, Share, Outlook 2032

Asthma Drug Market Size and Forecast (2025 - 2032), By Drug Class (Bronchodilators, Inhaled Corticosteroids, Combination Inhalers, Biologics), By Route of Administration (Oral, Inhaled, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography.

Report Code: HEA00176
Report Format: PDF + PPT + Excel
Download PDF Buy Now
Report Description

Report Highlights:

From USD 25.8 billion in 2022 to USD 35.6 billion by 2032, the worldwide asthma medicine market is expected to rise at a CAGR of 4.5%. With advanced healthcare infrastructure and high asthma incidence, North America now rules the industry.


Rising asthma prevalence worldwide, increased air pollution, growing geriatric population, and introduction of new biologic medicines are driving consistent increase in the asthma drug industry. Combining inhaler treatments is becoming more and more common because of its better efficacy and patient convenience. But availability of generic substitutes and patent expiries of several important pharmaceuticals could somewhat slow down market expansion.

 

Market Dynamics:

Market Trend: Changing market trend toward tailored biologic therapy and personalized medication for severe asthma
Particularly for severe and challenging to treat asthma cases, the asthma treatment market is seeing a paradigm shift towards tailored medicine methods. Targeting particular inflammatory pathways including IL-5, IL-4, and IgE, biologic treatments that offer customized treatment depending on individual patient features and asthma phenotypes are becoming more and more popular. For those who do not react sufficiently to traditional treatments, these focused therapies provide better results. Development in knowledge of asthma pathophysiology and biomarketer identification drives the trend. With many interesting candidates in late-stage clinical trials, major pharmaceutical corporations are heavily funding the creation of new biologics. With more efficient choices for severe asthma sufferers and driving market expansion in the next years, this trend is predicted to change the scene of asthma therapy.
 

Market Driver: Globally increasing frequency of asthma resulting from environmental elements and changing lifestyle choices
One of the main forces driving the expansion of the asthma medication market is the rising worldwide frequency of the condition. Growing air pollution, urbanization, changing lifestyles, and more contact to indoor allergens are among the elements driving this surge. The World Health Organization estimates that, especially in underdeveloped nations, over 339 million people worldwide suffer with asthma; the figure is rapidly rising. This expanding patient pool drives significant demand for asthma drugs in several pharmacological types. Furthermore driving governments and healthcare systems to concentrate on improved asthma management is the financial load of asthma, including direct healthcare expenses and indirect costs resulting from missed productivity. Further propelling market expansion are rising investments in asthma research, development of novel medicines, and better access to current medications resulting from this.
 

Market Restraint: Patent expiries and growing availability of generic substitutes influencing market income
The patent expiring of several important asthma drugs and the consequent arrival of generic alternatives provide a major obstacle for the asthma drug business. Price erosion and a smaller market share for branded products follow from generic copies joining the market at lower prices as patents for blockbuster drugs expire. Established inhaled corticosteroids and combination treatments, which have been cornerstones of asthma treatment, especially suffer from this tendency. Although low-cost generics help individuals and healthcare systems in terms of cost, their availability can greatly affect the income of big pharmaceutical corporations. This scenario is driving businesses—especially in the biologics area—to concentrate on creating new treatments in order to keep their market share. Still, the high development expenses and strict regulatory standards for new drug approvals create further difficulties that can hold down innovation in the asthma drug market.
 

Segment Analysis:

Biologics segment displaying fast expansion because of efficacy in severe asthma
Within the asthma medication market, the biologics category is predicted to keep growing rapidly over the forecast period. Particularly monoclonal antibodies targeting particular inflammatory pathways, biologic treatments have demonstrated amazing effectiveness in treating severe, refractory asthma cases not responding to conventional treatments. For those with difficult-to-treat asthma, these medications provide more individualized treatment strategies that help to lower aggravations and enhance quality of life. The huge unmet demand in this patient population and the premium pricing of biologic treatments are causing notable revenue growth in this market. Significant players are heavily funding the development and commercialization of new biologics, therefore accelerating the growth of the industry.
 

Regional Outlook:

North America dominates the market because of advanced healthcare infrastructure and great asthma frequency.
Currently holding the most position in the worldwide asthma medication market, North America is likely to keep its supremacy over the next years. High asthma frequency, established healthcare infrastructure, and early acceptance of new medicines help to explain the region's top position. With approximately 25 million people afflicted according to the CDC, the United States especially has one of the highest asthma rates worldwide. High healthcare costs and good reimbursement rules along with this sizable patient pool help to build a strong market for asthma drugs. Furthermore driving market expansion in the area are the presence of big pharmaceutical corporations and continuous research and development initiatives here. North America's status as a major market for asthma medications is even more confirmed by the great emphasis on biologics and tailored therapy for severe asthma.

 

Competitive Landscape:

Several big pharmaceutical companies fight for market share in this very competitive asthma drug industry. To get a competitive edge, key businesses are concentrating on creating novel treatments, especially in the biologics area. Companies trying to increase their product lines and regional reach often engage in strategic alliances, mergers, and acquisitions. Particularly in the areas related to inhaled corticosteroids and combination inhalers, generic manufacturers are also making major advances. Constant clinical research for new treatments and attempts to enhance current formulas define the industry. Companies are also funding smart inhalers and digital health solutions to improve illness management and drug adherence. In this always changing environment of a dynamic market, pricing pressures and regulatory challenges still define competitive strategies.

 

Major Players:

  • GlaxoSmithKline plc

  • AstraZeneca plc

  • Boehringer Ingelheim International GmbH

  • F. Hoffmann-La Roche Ltd

  • Novartis AG

  • Merck & Co., Inc.

  • Teva Pharmaceutical Industries Ltd.

  • Regeneron Pharmaceuticals, Inc.

  • Sanofi S.A.

  • Vectura Group plc

Table of Content

1. INTRODUCTION

   1.1. Market Definition

   1.2. Study Scope

   1.3. Currency Conversion

   1.4. Study Period (2022- 2031)

   1.5. Regional Coverage

2. RESEARCH METHODOLOGY

   2.1. Primary Research

   2.2. Secondary Research

   2.3. Company Share Analysis

   2.4. Data Triangulation

3. EXECUTIVE SUMMARY

   3.1. Global Asthma Drug Market (2018 – 2022)

   3.2. Global Asthma Drug Market (2023 – 2031)

      3.2.1. Market Segment By Drug Class (2023 – 2031)

      3.2.2. Market Segment By Route of Administration (2023 – 2031)

      3.2.3. Market Segment By Distribution Channel (2023 – 2031)

      3.2.4. Market Segment By Region (2023 – 2031)

4. MARKET DYNAMICS

   4.1. Market Trends

      4.1.1. Shift towards personalized medicine and targeted biologic therapies for severe asthma

      4.1.2. Increasing focus on digital health solutions and smart inhalers

      4.1.3. Growing emphasis on combination therapies for improved efficacy

   4.2. Market Drivers

      4.2.1. Rising prevalence of asthma globally due to environmental factors and changing lifestyles

      4.2.2. Technological advancements in drug delivery systems

      4.2.3. Increasing healthcare expenditure and improving access to asthma treatments

   4.3. Market Restraints

      4.3.1. Patent expiries and increasing availability of generic alternatives impacting market revenue

      4.3.2. Stringent regulatory requirements for new drug approvals

   4.4. Porter's Five Forces Analysis

      4.4.1. Threat of New Entrants

      4.4.2. Bargaining Power of Buyers/Consumers

      4.4.3. Bargaining Power of Suppliers

      4.4.4. Threat of Substitute Products

      4.4.5. Intensity of Competitive Rivalry

   4.5. Supply Chain Analysis

   4.6. Pricing Analysis

   4.7. Regulatory Analysis

   4.8. Pipeline Analysis

5. BY DRUG CLASS (MARKET VALUE (US$ MILLION) – 2022-2031*)

   5.1. Bronchodilators

   5.2. Inhaled Corticosteroids

   5.3. Combination Inhalers

   5.4. Biologics

6. BY ROUTE OF ADMINISTRATION

   6.1. Oral

   6.2. Inhaled

   6.3. Intravenous

7. BY DISTRIBUTION CHANNEL

   7.1. Hospital Pharmacies

   7.2. Retail Pharmacies

   7.3. Online Pharmacies

8. GEOGRAPHY

   8.1. North America

      8.1.1. United States

      8.1.2. Canada

      8.1.3. Mexico

   8.2. South America

      8.2.1. Brazil

      8.2.2. Argentina

      8.2.3. Rest of South America

   8.3. Europe

      8.3.1. Germany

      8.3.2. United Kingdom 

      8.3.3. France

      8.3.4. Italy

      8.3.5. Spain

      8.3.6. Russia

      8.3.7. Rest of Europe

   8.4. Asia-Pacific

      8.4.1. China

      8.4.2. Japan

      8.4.3. India

      8.4.4. Australia

      8.4.5. South Korea

      8.4.6. Rest of Asia-Pacific

   8.5. Middle-East

      8.5.1. UAE

      8.5.2. Saudi Arabia

      8.5.3. Turkey

      8.5.4. Rest of Middle East

   8.6. Africa

      8.6.1. South Africa

      8.6.2. Egypt

      8.6.3. Rest of Africa

9. COMPETITVE LANDCAPE

   9.1. Key Developments

   9.2. Company Market Share Analysis

   9.3. Product Benchmarking

10. SWOT ANALYSIS

11. COMPANY PROFILES

    11.1. GlaxoSmithKline plc

    11.2. AstraZeneca plc

    11.3. Boehringer Ingelheim International GmbH

    11.4. F. Hoffmann-La Roche Ltd

    11.5. Novartis AG

    11.6. Merck & Co., Inc.

    11.7. Teva Pharmaceutical Industries Ltd.

    11.8. Regeneron Pharmaceuticals, Inc.

    11.9. Sanofi S.A.

    11.10. Vectura Group plc

    11.11. Other major players

    11.12. Emerging companies (*LIST NOT EXHAUSTIVE)

12. MARKET OPPORTUNITIES

Scope of the Report

By Drug Class:

  • Bronchodilators

  • Inhaled Corticosteroids

  • Combination Inhalers

  • Biologics

By Route of Administration:

  • Oral

  • Inhaled

  • Intravenous

By Distribution Channel:

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

By Region:

  • North America

  • Europe

  • Asia-Pacific

  • Latin America

  • Middle East & Africa

Frequently Asked Questions

We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.

At aurorawaveintellects.com, we believe that every industry is important to us. Our extensive team of analysts give equal focus to various industries in order to cater to our client needs, some of them being – Healthcare & Pharma, Medical, Automotive, Electric, Chemical, Manufacturing, Energy & Power, Consumer Goods etc.
Our core expertise lies in gaining deeper insights from reliable and trusted voices in the market. We always analyse market trends over the course of multiple years and examine which topics are most relevant to our clients. We pay a great deal of attention to emerging trends, niche technologies, and the latest innovations and research to bring out the best that we can offer.
We understand that every client is different and so is their requirement. While we try to gauge our clients’ needs, we are unable to cover every possible angle of a market in an off-the-shelf report. Hence, we also provide customization options to our reports to suit your needs. If you would like to know what information we can provide about a particular topic, please get in touch with us at info@aurorawaveintellects.com.
Our Research Reports give insights into a gamut of qualitative and quantitative topics. Every Research Report contains the following: • Market landscape • Market size • Market segmentation • Market drivers, challenges, and trends • Vendor landscape For more detail on what a specific report contains, click on report details to know more. If you would like to know what information we can provide about a particular topic, please get in touch with us at info@aurorawaveintellects.com
Our Research Reports are frequently updated with new data and predictions. We also have reports from previous years for specific topics. If you need help, contact us at info@aurorawaveintellects.com and we will be happy to assist you for your query.

We at aurorawaveintellects.com offer mainly 3 types of licenses:

• Single User: Research Report copy can be distributed to a single user only

• Multi User: Research Report distribution is restricted up to 5 users.

• Corporate License :Research Report can be distributed across the company.

Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:

• PDF

• Word Document

• PPT

To purchase a research report, you can browse through various categories, industries or topics and choose a particular report. Next, choose a license type and add the report to your cart. Then simply check out and complete the payment transaction and your report will be delivered to your inbox via email..

Following modes are available for making the payment:

• Online Payment (Visa Card, Master Card, Stripe)

• Razorpay

• Net Banking

• Bank Wire Transfer

At Research Reports Inc., we believe in providing the best value and offering competitive pricing to our customers to reflect that value. However, if you would still like to find out about discounts and offers, please get in touch with us at info@aurorawaveintellects.com.
Yes, you can purchase individual sections of the report. Please get in touch with us at info@aurorawaveintellects.com with your specific request, and we will support you accordingly.
As soon as the purchase process is over and the payment transaction is complete, you will receive the receipt via email.
The purchased Research Report is delivered to your registered email address within 48 hours of receipt of payment. If in case you did not, please check your spam folder. If you still haven’t received it, please get in touch with us at info@aurorawaveintellects.com
If you would like to receive a hard copy of the report, please get in touch with us at info@aurorawaveintellects.com with details about your purchase and we will process the same.
At aurorawaveintellects.com, we offer strong after-sales support with every purchase. Feel free to call us or email us with your queries and we will ensure they are addressed appropriately.
The Research Reports we provide are designed to cater to all market participants across the value chain. However, we do understand that every report may or may not meet the exact client requirement. For any specific change or customization in the report, please get in touch with us at info@aurorawaveintellects.com with your specific request, and we will support you accordingly.

Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:

• Email: info@aurorawaveintellects.com

• United Kingdom: ++91 7382742511